May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Inhibition of Diabetic Leukostasis and Blood–Retinal Barrier Breakdown With a Soluble Form of a Receptor for Advanced Glycation End Products
Author Affiliations & Notes
  • Y. Kaji
    Ophthalmology, Univ of Tsukuba Inst Clin Sci, Ibaraki, Japan
  • T. Usui
    Ophthalmology, Univ of Tokyo Graduate School of Medicine, Tokyo, Japan
  • S. Ishida
    Ophthalmology, Keio University School of Medicine, Tokyo, Japan
  • K. Yamashiro
    Ophthalmology, Kyoto University Graduate School of Medicine, Kyoto, Japan
  • S. Amano
    Ophthalmology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
  • T. Oshika
    Ophthalmology, Univ of Tsukuba Inst Clin Sci, Ibaraki, Japan
  • A.P. Adamis
    Eyetech Research Center, Lexington, MA
  • Footnotes
    Commercial Relationships  Y. Kaji, None; T. Usui, None; S. Ishida, None; K. Yamashiro, None; S. Amano, None; T. Oshika, None; A.P. Adamis, None.
  • Footnotes
    Support  Ministry of Education Science Sports and Culture Grant–in–Aid for Young Scientists, 16791042, 2004
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 404. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Kaji, T. Usui, S. Ishida, K. Yamashiro, S. Amano, T. Oshika, A.P. Adamis; Inhibition of Diabetic Leukostasis and Blood–Retinal Barrier Breakdown With a Soluble Form of a Receptor for Advanced Glycation End Products . Invest. Ophthalmol. Vis. Sci. 2005;46(13):404.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The interaction of advanced glycation end products (AGE) with their receptors is hypothesized to be involved in the development of diabetic retinopathy. However, there are no direct data showing the involvement of AGE receptors in diabetic retinopathy. In the present study, we analyzed the role of an AGE receptor, receptor for AGE (RAGE), in the development of the diabetic retinopathy in vivo. Methods: C57/BJ6 male mice were made diabetic with intraperitoneal injection of streptozocin. Three months following the onset of diabetes, the soluble form of RAGE (sRAGE) or mouse serum albumin was injected intraperitoneally at 20 microgram/day for fourteen days. After the final injection, blood–retinal barrier breakdown and retinal leukostasis were quantified. Results: Experimental diabetes was associated with blood–retinal barrier breakdown and the leukostasis in the C57/BJ6 mice. The blood–retinal barrier breakdown and leukostasis in the diabetic C57/BJ6 mice were accompanied by the increased expression of VEGF and ICAM–1 in the retina. The systemic administration of sRAGE significantly inhibited the blood–retinal barrier breakdown and the leukostasis in diabetic mice. Conclusions: These data indicate that AGEs induced blood–retinal barrier breakdown and the retinal leukostasis, which are characteristic clinical symptoms of diabetic retinopathy. Furthermore, these data demonstrate that blocking AGE bioactivity can be used for the treatment of diabetic retinopathy.

Keywords: diabetic retinopathy • glycoconjugates/glycoproteins 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×